BIOMARKERS FOR THERAPEUTIC RESPONSE IN CERVICAL CANCER

Cervical cancer, a potentially preventable disease, remains the second most common malignancy in women worldwide. Despite the tremendous progress that has been achieved in the screening and management of cervical cancer, there is still a need for clinically relevant prognostic biomarkers to monitor the response of patients to various therapies and to predict the chances of recurrence and recovery. Since cancer recurrence is the most common treatment failure in patients with advanced tumor, increasing knowledge about new biologic markers and better ability to predict risk of cancer recurrence is very important for construction of more effective treatment strategies. The biomarkers, which indicate the response of cancer patients to various therapy, predict response to particular therapies and choose the drug that, most likely to yield a favorable response in a given patient, identify patients with a high probability of adverse effects of a treatment and determine whether a therapy is having the intended effect on a disease and whether adverse effects arise. In this literature study we have done a survey of the identified biomarkers that will help in predicting therapeutic response of cervical cancer under the three classes, ie, apoptotic markers, angiogenic markers and other miscellaneous prognostic markers